AUTOGRAFTING FOR LYMPHOMA

自体移植治疗淋巴瘤

基本信息

  • 批准号:
    6395686
  • 负责人:
  • 金额:
    $ 22.14万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2000
  • 资助国家:
    美国
  • 起止时间:
    2000-03-13 至 2001-01-31
  • 项目状态:
    已结题

项目摘要

It is the objective of our studies to improve the results of treatment with high dose therapy and autografting in Hodgkin's disease and the non-Hodgkin's lymphomas. We intend to accomplish this goal through the study of novel preparatory regimens and post-transplant immunotherapy. Complementary pathology studies are planned to better define biologic correlates of the clinical results. The proposed clinical studies build on our previous research in these diseases. A new preparatory regimen (CCNU, VP16, cyclophosphamide) developed at Stanford University will be evaluated in patients with low risk Hodgkin's disease. Multiple cycle high dose therapy has been developed to reduce relapse in high risk Hodgkin's disease patients. We will compare the efficacy and toxicity of high dose sequential chemotherapy with our standard preparatory regimen in a Phase III trial in non-Hodgkin's lymphoma. Correlations will be made with a number of biologic parameters assessed in lymphoma tissues in order to further elucidate factors that may predict the treatment outcome after high dose therapy and autografting. All autografted patients will be studied by sensitive molecular and cytogenetic techniques designed to predict genomic instability and the risk for treatment- related myelodysplasia or acute leukemia. In collaboration with investigators in Project III, we will study the feasibility and toxicity of infusing cytokine-induced killer cells into patients with refractory non-Hodgkin's lymphoma. These CIK cells represent a novel therapeutic which, when used as an adjunct to high dose therapy and autografting, may reduce the major problem of relapse after autografting. The studies in Project II are based on past accomplishments in the research laboratory and the clinic. Analysis of previous experience allows us to define risk groups in Hodgkin's disease and structure preparatory regimens accordingly. We plan a comprehensive approach to the study of non-Hodgkin's lymphoma by characterizing lymphoma tissues, purging lymphoma from the apheresis product, comparing two preparatory regimens, and introducing a novel post-transplant immunotherapy to the clinic. The potential for myelodysplasia or acute leukemia as a late effect of high dose therapy will be studied prospectively in all patients. Project II will serve as a clinical resource for other subprojects.
我们研究的目的是改善治疗效果

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

SANDRA J. HORNING其他文献

SANDRA J. HORNING的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('SANDRA J. HORNING', 18)}}的其他基金

Autografting for Lymphoma
自体移植治疗淋巴瘤
  • 批准号:
    8260362
  • 财政年份:
    2011
  • 资助金额:
    $ 22.14万
  • 项目类别:
Autografting for Lymphoma
自体移植治疗淋巴瘤
  • 批准号:
    7212897
  • 财政年份:
    2007
  • 资助金额:
    $ 22.14万
  • 项目类别:
EFFICACY OF ANTI-CD20 ANTIBODY IN LYMPHOCYTE PREDOMINANT HODGKIN'S DISEASE
抗 CD20 抗体在淋巴细胞为主型霍奇金病中的疗效
  • 批准号:
    7605162
  • 财政年份:
    2007
  • 资助金额:
    $ 22.14万
  • 项目类别:
CLINICAL TRIAL: EVALUATE THE EFFICACY OF ANTI-CD20 ANTIBODY IN LYMPHOCYTE PREDOM
临床试验:评估抗 CD20 抗体在前淋巴细胞中的功效
  • 批准号:
    7717845
  • 财政年份:
    2007
  • 资助金额:
    $ 22.14万
  • 项目类别:
EFFICACY OF ANTI-CD20 ANTIBODY IN LYMPHOCYTE PREDOMINANT HODGKIN'S DISEASE
抗 CD20 抗体在淋巴细胞为主型霍奇金病中的疗效
  • 批准号:
    7375191
  • 财政年份:
    2005
  • 资助金额:
    $ 22.14万
  • 项目类别:
EFFICACY OF ANTI-CD20 ANTIBODY IN LYMPHOCYTE PREDOMINANT HODGKIN'S DISEASE
抗 CD20 抗体在淋巴细胞为主型霍奇金病中的疗效
  • 批准号:
    7202019
  • 财政年份:
    2004
  • 资助金额:
    $ 22.14万
  • 项目类别:
TREATMENT OF PATIENTS WITH LARGE B-CELL LYMPHOMA
大 B 细胞淋巴瘤患者的治疗
  • 批准号:
    7202057
  • 财政年份:
    2004
  • 资助金额:
    $ 22.14万
  • 项目类别:
A Phase II Study: Rituximab, rhuMAb VEGF (bevacizumab)
II 期研究:利妥昔单抗、rhuMAb VEGF(贝伐珠单抗)
  • 批准号:
    6980946
  • 财政年份:
    2003
  • 资助金额:
    $ 22.14万
  • 项目类别:
Evaluate the Efficacy of Anti-CD20 Antibody in Hodgkin's
评估抗 CD20 抗体在霍奇金氏病中的疗效
  • 批准号:
    6980890
  • 财政年份:
    2003
  • 资助金额:
    $ 22.14万
  • 项目类别:
PHASE II STUDY OF IODINE 131 ANTI BI ANTIBODY FOR NON HODGKINS LYMPHOMA
碘131抗双抗体治疗非霍奇金淋巴瘤的II期研究
  • 批准号:
    6486028
  • 财政年份:
    2000
  • 资助金额:
    $ 22.14万
  • 项目类别:

相似海外基金

Precision genome editing with tandem autologous transplantation as a therapy for multiple severe immune-mediated diseases
精准基因组编辑与串联自体移植治疗多种严重免疫介导疾病
  • 批准号:
    MR/T030410/1
  • 财政年份:
    2021
  • 资助金额:
    $ 22.14万
  • 项目类别:
    Research Grant
Development and research of function maintenance culture method and new autologous transplantation method of human salivary gland cells
人唾液腺细胞功能维持培养方法及自体移植新方法的开发研究
  • 批准号:
    19K19186
  • 财政年份:
    2019
  • 资助金额:
    $ 22.14万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Osteochondral regeneration by autologous transplantation of abundant stem cells cultured high-densely
通过高密度培养的丰富干细胞自体移植实现骨软骨再生
  • 批准号:
    19H03129
  • 财政年份:
    2019
  • 资助金额:
    $ 22.14万
  • 项目类别:
    Grant-in-Aid for Scientific Research (B)
Investigation of tissue architecture of abdominal wall endometriosis for ovarian autologous transplantation to abdominal wall
腹壁子宫内膜异位症腹壁自体卵巢移植的组织结构研究
  • 批准号:
    18K09266
  • 财政年份:
    2018
  • 资助金额:
    $ 22.14万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
autologous transplantation of adipose tissue derived mesenchymal stromal cells to the old myocardial infarction heart
自体脂肪组织间充质干细胞移植至陈旧性心肌梗死心脏
  • 批准号:
    18K15839
  • 财政年份:
    2018
  • 资助金额:
    $ 22.14万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Development of heart regenerative therapy for old myocardial infarction by autologous transplantation with iPSC-derived cardiomyocytes
利用iPSC来源的心肌细胞自体移植治疗陈旧性心肌梗死的心脏再生疗法的进展
  • 批准号:
    17K16589
  • 财政年份:
    2017
  • 资助金额:
    $ 22.14万
  • 项目类别:
    Grant-in-Aid for Young Scientists (B)
Development of a regenerative therapy for spinal cord injury by autologous transplantation of bone marrow derived mononuclear cell.
通过骨髓来源的单核细胞自体移植开发脊髓损伤再生疗法。
  • 批准号:
    24580469
  • 财政年份:
    2012
  • 资助金额:
    $ 22.14万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Autologous transplantation of conjunctival epithelial stem cells based on epigenetical control.
基于表观遗传控制的结膜上皮干细胞自体移植。
  • 批准号:
    24659757
  • 财政年份:
    2012
  • 资助金额:
    $ 22.14万
  • 项目类别:
    Grant-in-Aid for Challenging Exploratory Research
Basic study of autologous transplantation of ex vivo expanding macrophages to secondary lymphedema
离体扩增巨噬细胞自体移植治疗继发性淋巴水肿的基础研究
  • 批准号:
    23791286
  • 财政年份:
    2011
  • 资助金额:
    $ 22.14万
  • 项目类别:
    Grant-in-Aid for Young Scientists (B)
PRIMATE PLURIPOTENT CELLS FOR AUTOLOGOUS TRANSPLANTATION
用于自体移植的灵长类多能细胞
  • 批准号:
    8173333
  • 财政年份:
    2010
  • 资助金额:
    $ 22.14万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了